Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesSales of Property, Plant and EquipmentShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

TELA Bio (TELA) Net Cash Flow (2018 - 2025)

TELA Bio (TELA) has 8 years of Net Cash Flow data on record, last reported at -$5.4 million in Q3 2025.

  • For Q3 2025, Net Cash Flow rose 40.24% year-over-year to -$5.4 million; the TTM value through Sep 2025 reached $12.4 million, up 130.61%, while the annual FY2024 figure was $5.9 million, 22.91% up from the prior year.
  • Net Cash Flow reached -$5.4 million in Q3 2025 per TELA's latest filing, up from -$7.7 million in the prior quarter.
  • Across five years, Net Cash Flow topped out at $35.2 million in Q4 2024 and bottomed at -$12.2 million in Q4 2022.
  • Average Net Cash Flow over 5 years is -$2.3 million, with a median of -$8.6 million recorded in 2021.
  • Peak YoY movement for Net Cash Flow: skyrocketed 767.96% in 2023, then plummeted 130.4% in 2024.
  • A 5-year view of Net Cash Flow shows it stood at -$9.7 million in 2021, then dropped by 26.23% to -$12.2 million in 2022, then rose by 8.38% to -$11.2 million in 2023, then skyrocketed by 413.55% to $35.2 million in 2024, then tumbled by 115.3% to -$5.4 million in 2025.
  • Per Business Quant database, its latest 3 readings for Net Cash Flow were -$5.4 million in Q3 2025, -$7.7 million in Q2 2025, and -$9.7 million in Q1 2025.